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Organs-On-CHiPs: ExPlOring THE UTiliTy Of BiOsynTHEsisEd Organ 
TissUE TO imPrOvE EffiCiEnCy Of THE drUg dEvElOPmEnT PrOCEss
Middelkamp H, Stamatialis D, Jzerman MJ
University of Twente, Enschede, The Netherlands
Objectives: Drug development is an expensive process, partly because of the 
required testing for human toxicity and efficacy of drugs. Organ-on-a-chip is a 
multichannel 3D microfluidic cell culture chip that simulates the activities and 
mechanics of entire organs and organ systems. Organ-on-chip is expected to 
reduce the amount of animal testing, and may increase efficiency of drug devel-
opment. For instance, when organ-on-a-chip is used to replace or add to in vivo 
testing experiments, 7.5-10% of drug development costs may be saved. This study 
explores the expected advantages of organ-on-chip technologies as well as poten-
tial barriers to implement. MethOds: Stakeholders (n= 50) in this research were 
employees of pharmaceutical companies (n= 18, 36%), developers of microfluidic 
systems and university employees affiliated with organ-on-a-chip/ microfluidic 
systems development and/or drug development (n= 22, 44%). Stakeholders were 
asked their expert opinions about the potential benefits of organ-on-chip using a 
survey (LimeSurvey), which was based on information previously acquired from 
expert interviews. Results: According to stakeholders, organ-on-a-chip may be 
most promising in basic research stage (90%) or the preclinical stage (88%) of drug 
development. Simple models can be used for target identification (70%) while com-
plex models could lead to replacement of animals (78%). However, head-to-head 
studies are needed to change regulations, leaving organ-on-a-chip as an add-on in 
drug development for now. There are significant differences between stakeholders 
opinions about advantages. Most promising organ-on-chip developments should 
target organs like Liver (20%), heart (18%) and kidney (17%). cOnclusiOns: Organ-
on-a-chip can be a valuable add-on in the drug development process, in particular in 
basic research or preclinical stage of the drug development process. Given the very 
early stage of organ-on-chip technologies, it is hard to predict return on investment.
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THE CUrrEnT landsCaPE and ExPECTEd CHangEs in fOrmUlary 
managEmEnT
Brook RA1, Smeeding JE1, Sax MJ2
1The TPG-NPRT, Glastonbury, CT, USA, 2The Pharmacy Group (TPG), Glastonbury, CT, USA
Objectives: Understand how medical and pharmacy directors (MDs+PDs) and 
pharmacy and therapeutics (P&T) committees from public and private health 
plans, insurers, and PBMs administer formularies, make formulary decisions today, 
and expected changes for the future. MethOds: Online interactive survey of US 
MDs+PDs. Results: Fifty-four percent of respondents were MDs, the remainder 
mostly pharmacists. Most worked for a health plan (83.6%) and 39.6% of the plans 
were local; 35.4% national; and 25.0% regional and 86% were involved in formulary 
decisions. AMCP-dossiers are: not-required (52.2%), used for back-ups (39.1%) and 
used as a basis for reviews (8.9%). Clinician-administered products (ex. office admin-
istered injections) are always under the medical-benefit (67.3%), no plans exclusively 
under the pharmacy-benefit, the remaining 32.7% determine the benefit using cost-
thresholds; most plans (72.9%) do not anticipate a change, 18.8% expect a change 
before 12-2016, 2.1% before 12-2018. Mental health (MH) products were carved-out 
in 1/3 of plans, conditions with multiple MH therapies required generics first (45%), 
mandatory step-therapy (37.5%) and require care by a psychiatrist (17.5%). Most 
were happy with their pharmacy-benefit design, the most requested changes were 
more restrictive management programs; followed by changes in tiers/co-pays. Most 
respondent didn’t desire a change to their P&T process; desired changes included 
more frequent meetings/time; and the use of Comparative Effectiveness Research. 
Most advisors happy with their plan’s medical-benefit management, the most 
desired changes included integration of benefits/departments and more restrictive 
networks. Top current medical concerns: Cancer/oncology, Diabetes and Hepatitis-C. 
Top current budget concerns Hepatitis-C, Cancer/oncology, and Diabetes. Future 
areas of concern include biosimilars, immunomodulators, cardiovascular/heart dis-
ease; multiple sclerosis; biologics; orphan/rare diseases. cOnclusiOns: Managed 
care uses a variety to tools for formulary managment, including benefit type, man-
datory generics and step-therapy. Understanding how decisions are made today 
and concerns for today and in the future can help guide product development.
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(KSAU-HS), Ryiadh, Saudi Arabia
Objectives: Pharmacy Information System (PIS) in hospital pharmacies can opti-
mize the institutional Pharmacy Benefit Management Program (PBMP) and patients’ 
outcomes if the PIS has high detection and reporting capabilities. The aim of the 
study is to explore and investigate the PIS capabilities in tertiary and secondary 
hospitals in Riyadh city, Saudi Arabia. MethOds: A cross-sectional survey tar-
geted pharmacy mangers in hospital with inpatient and outpatient pharmacies 
in Riyadh City in 2014. The survey gathered information about PIS characteristics 
such as detection capabilities (drug interactions, drug allergy, etc.), drug utilization 
reporting capabilities, and PIS integration with Electronic Medical Record (EMR) 
Computerized Physician Ordered Entry (CPOE). Results: Of 30 hospital pharmacies, 
23 (76.6%) pharmacy managers responded, only 21(70%) hospital pharmacies met 
the inclusion criteria, 15 (71.4%) are governmental and 6 (28.6%) are private hospi-
tals, 18(85.7% ) hospitals have EMR, 19 (90.5%) hospital pharmacies have PIS. Of the 
14(66.67%) hospitals with CPOE, only 9 (64.2%) have CPOE that are integrated with 
inpatient and outpatient PIS. For the PIS capabilities, out of the 21 hospitals; 8 (38.1%) 
were able to detect incorrect dose and duration, 7 (33.3%) for drug-drug interaction, 
5(23.8%) for drug-disease Interaction, 6 (28.6%) for contraindication, 6(28.6%) for the 
pital beds changed significantly in 2007 and 2011. The aim of our study is to assess 
the efficiency of the long-term care system in Hungary, to examine the effect of 
these regulations. MethOds: We used input-oriented Data Envelopment Analysis 
to calculate technical- and scale efficiency. We chose five variables: number of 
beds, average length of stay (inputs), number of discharged patients, amount of 
fee paid by the NHIF, and the number of days (outputs). We examined years 2006 
(N= 109), 2010 (N= 121) and 2013 (N= 111). Units operating with less than 50 bed 
were excluded. Data were collected from databases of the Hungarian National 
Health Insurance Fund. For our calculations we used the DEAP 2.1. Results: In 
these years all of the selected variables were increasing, except the average length 
of stay. Technical efficiency was 94.2% in 2006, 88.6% in 2010 and 95.1% in 2013. 
Scale efficiency was 91.4% in 2006, 90.9% in 2010, 92.7% in 2013. Ratio of technically 
efficient units: 24.8% of units were fully efficient in 2006 (n= 27), 19.8% (n= 24) in 
2010, and 35.1% (n= 39) in 2013. The ratio of units achieved 100% scale efficiency 
was 12.8% (n= 14), 5.8% (n= 7) and 17.1% (n= 19). Almost all units were “increasing 
return to scale”, which means they could increase their level of efficiency, if they 
had larger size (more beds). cOnclusiOns: Based on the results we can say 
that the units have relatively high values in all years. Efficiency scores decreased 
slightly in 2006-2010, but showed improvement in the next three years. We can 
conclude that the Hungarian long-term care needs to reduce the number of units, 
but needs to improve the size of them.
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THE COmPETiTiOn BETwEEn drUgsTOrE and Primary CarE and 
TrEaTmEnT CHOiCE Of PaTiEnTs in THE COnTExT Of EssEnTial mEdiCinE 
POliCy in rUral CHina
Zuo G
Shandong University, Jinan, China
Objectives: Since 2009, Chinese government has constructed essential medicines 
policy of centralized purchasing, uniform distribution, compulsory use and “zero-
mark-up” (i.e. no-profit) sale for essential medicines in primary care, but the policy 
does not regulate the drugstore. As a result, competition relationship between 
drugstore and primary care has changed in rural China. This study aims to inves-
tigate the competition relationship between drugstore and primary care in rural 
China. MethOds: We collect information of treatment procedure of 1015 patients 
from 18 villages at three counties of Shandong Province in China with different eco-
nomic and geographical environment from January to May 2015 by the household 
investigation, supported by National Natural Science Foundation of China [Grant 
Number 71203124]. Competition relationship between drugstore and primary care is 
measured as growth rate of the number of drugstore and primary care. The indica-
tor of patients’ treatment choice is proportion rate of purchasing pharmaceuticals 
channel. The relationship between competition relationship and patients’ choice 
is identified by interviews with stakeholders such as the leader of County Health 
Bureau and primary care. Results: From 2010 to 2014, the number of drugstore in 
poorest and richest County has increased respectively 2.43 times and 0.18 times. 
However, the number of primary care keeps unchanged. At the same time, the treat-
ment choice of patients including village clinic(46.31%), drugstore(22.17%), county 
hospitals(7.49%), township hospitals(6.60%) and other hospitals(17.44%) . Drugstore 
has become the second biggest pharmaceuticals sale channel in rural china. The 
reason for this issue is the limit of only using essential medicines by no-profit 
sale for primary care but not for drugstore. cOnclusiOns: Essential medicine 
policy has changed the competition relationship of pharmaceutical market in rural 
China, which affects treatment choice of patients. The treatment choice of patients 
is threatening the development of essential medicine in rural China. Keywords: 
essential medicine; competition; drugstore; primary care
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Objectives: Determine how medical and pharmacy directors (MDs+PDs) of US 
health plans, insurers, and PBMs manage specialty pharmaceuticals (SPs). In 
2014 SPs accounted for one-third of spending, up from 23% in 2009. MethOds: 
Managed care (MC) MDs+PDs from public and private plans covering multiple types 
of members completed an online interactive survey of: advisor+plan information; 
use of specialty-pharmacies, and current/future coverage of SPs. Results: Fifty-
four percent of respondents were MDs, the remainder mostly pharmacists. Most 
worked for a health plan (83.6%) and the plans were: 39.6%= local; 35.4%= National; 
25.0%= regional. SP providers were restricted by 53.7% of the plans, of those with 
restrictions: the majority restrict SP provider services to a small set under contract 
(63.0%), 17.4% allow any SP; and 6.5% only restricted products available through mul-
tiple specialty-pharmacies. Plans covered clinician-administered products (injec-
tions/infusions) under the medical-benefit (MB= 67.3%); none exclusively under the 
pharmacy-benefit (PB= 0%); and 32.7% based on cost-thresholds. Most plans (72.9%) 
do not anticipate a change, 18.8% expect a change before 12-2016 and 2.1% prior to 
12-2018. Oral Biologics (OBs) were managed under the PB 78.3%; 10.9% under the 
MB; the other 10.9% based on cost-thresholds. Benefits for OBs are not expected to 
change by 71.1% of the plans, 11.1% were currently making changes; 13.3% expect 
changes prior to 12-2016; and 4.4% before 12-2018. SP and OB co-pays vary by group 
and benefit design and are shifting from fixed to percent co-pays. Responses to open 
ended questions placed SP products at the top causes for concern currently, and 
for the coming years. cOnclusiOns: Expenditures for SP products and the use of 
specialty pharmacy will continue to grow. The environment for MC is undergoing a 
series of changes, and payor medical directors and pharmacy directors, who com-
monly serve as P&T Committee members will guide how changes to benefit and 
plan design are implemented in the future.
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remain at year 2013 level, and these were then combined with official population 
forecasts. Results: Altogether 160,952 individuals (81% of all inhabitants) had at 
least one healthcare contact during the follow up. Primary and secondary healthcare 
services had been used by 155,631 and 59,589 patients, respectively. The average 
annual cost per patient was 1,853€ . The average cost in primary and secondary 
healthcare was 808€ and 2,895€ , respectively. Variation was wide across the dif-
ferent ages (Primary healthcare, range: 346€ –5,645€ ; Secondary healthcare, range: 
1,282€ –4,474€ ). Due to aging of the population only, according to the future projec-
tions, in the year 2025, the total primary healthcare costs are 21% and secondary 
healthcare costs 14% higher than in 2013. cOnclusiOns: With respect to costs, 
aging of the population affects primary healthcare more than specialized health-
care. Thus, the healthcare utilization should be regarded as one entity taking into 
account both primary and secondary healthcare services. If the overall treatment 
process, from primary care to secondary care and sometimes back to primary care, 
is not taken in to account, this will lead to suboptimal decision making.
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HEalTH sErviCEs UTilizaTiOn By dEngUE PaTiEnT in Brazil, 2012 – 2013: a 
mUlTiCEnTEr sTUdy
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Objectives: To describe health service utilization (HSU) patterns of dengue cases 
by age, severity of illness, and healthcare sector, in Brazil during an epidemic den-
gue transmission period. MethOds: A multicenter cohort study was conducted 
in 2012-2013 at four Brazilian endemic regions. Patients were ascertained in units 
and hospitals from both public and private sectors. Data collection was performed 
by interviewing 15-20 days after the onset of symptoms and review of medical 
records of hospitalized patients. HSU specific information included: access and 
type of healthcare service, type and quantity of diagnostic, laboratory and imag-
ing tests, medical procedures, and medications. Results: A total of 2,035 (91.5%) 
dengue cases were recruited to our study: 1,657 (81.4%) were outpatients and 378 
(18.6%) inpatients; 1,361 (66.9%) were assisted at public and 674 (33.1%) at private 
sector; 398 (19.6%) children and 1,635 (80.4%) adults. Public sector has higher medi-
cal visits average which ranged from 1.2 in Teresina (Northeast) to 4.2 in Goiânia 
(Midwest) for outpatients, and from 3.2 in Goiânia to 5.0 in Teresina for inpatients. 
Hospital length of stay varied from 3-4 days. Full blood count was carried out in 
80% of cases; in 75% of adults, in both outpatients and inpatients. X-ray tests were 
performed in 8.2% of outpatients and 26.2% of inpatients, with most adults (75.0%). 
Frequently outpatients and inpatients reported medication use, 71.0% and 65.9% 
respectively, specially at public sector (75.0%). cOnclusiOns: Our results show 
that HSU patterns of dengue cases have extensive variations regarding healthcare 
sector, severity of illness, and different regions of Brazil. The HSU could be affected 
by dengue clinical guidelines utilized in healthcare service.
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dOEs THE lEgal rEgUlaTiOn Of PrOmOTing PHarmaCEUTiCal ParallEl 
imPOrTs HElPs TO CrEaTE savings fOr THE sTaTUTOry HEalTH 
insUranCE (gkv) in gErmany?
Leisten M, Brakmann D, Münchberg F, Wiberny S
Janssen-Cilag GmbH, Neuss, Germany
Objectives: In Germany parallel imports does not only exist due to economic 
reasons like arbitrage principle, but due to special legislative support. According to 
law, pharmacies have to fulfil a predetermined import quota to achieve a certain 
efficiency reserve which should help generating higher savings for the statutory 
health insurance. Prices of imports are only cost efficient if they are fulfilling a 
minimum price difference which is 15% or 15 Euro below the prices of originals. 
The objective is to determine whether imports are price efficient and if they obtain 
the legally implemented savings. MethOds: This analysis evaluates data from 
IMS-Database which covers all redeemed GKV receipts. Imports were identified by 
pharmacy number (PZN). Afterwards they were ordered by Anatomical Therapeutic 
Chemical (ATC)-Coding and listed separately for GKV-sales and market share. 
Market share was identified by units sold, sales on basis of manufactures price. 
Prices were taken from a public price list (Lauer-Taxe). For overall savings publi-
cized data were used (Arzneimittel-Atlas). Evaluation period was 2013. Results: 
Imports are focussing on special therapeutics, mainly covering Neurologics (ATC1 
“N”) and Immunsuppressiva (ATC1 “L”). Both indications received a market share 
of 38.7% with sales of 2.5 bio. euro. By looking at the top 5 imports with highest 
sales cost efficient prices according to legal rule are only apparent in 3 of 5 cases 
(absolute rating) and 1 of 5 cases (relative rating). In general, prices of imports are 
oriented to prices of originals and sometimes even excess them. Annual savings 
are 63.5 mio. euro. cOnclusiOns: Imports are focussing on special therapeutic 
areas which mainly lead to high margins for importers. Prices are not efficiently 
according to legal rule so that the expected savings does not result. Therefore 
the existing regulation of import quota should be disestablished. Imports should 
regulate themselves by the competition of the market but without additional 
support by legislation.
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gEnEral assEssmEnT Of UnliCEnsEd anTinEOPlasTiC and 
immUnOmOdUlaTing mEdiCinE UsagE in TUrkEy
Tuna E1, Kockaya G2, Yenilmez FB1, Dogan E3, Vural IM3, Akbulat A3, Artiran G3, Tatar M1, 
Unal O3
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3Turkish Medicines and Medical Devices Agency, Ankara, Turkey
formulary non-adherence and 8 (38.1%) for early refill detection. Only six (28.6%) 
hospitals with PIS have the capability to generate four types of reports(ranking 
physicians by utilization, drug they prescribe, most utilized drug by number of 
patients, most utilized drug by diagnosis). cOnclusiOns: Adopting PIS in Saudi 
hospitals is improving comparing to 2003 study, however, the integration of the 
EMR and CPOE still not to the expected level. To ptimize the institutional Pharmacy 
Benefit Management Program (PBMP), the detection and reporting capabilities of 
the PIS should be improved to facilitate prescribing decision making process, and to 
improve concurrent, prospective, and retrospective drug utilization review process.
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amCP fOrmaT
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Objectives: Both the HTA Core Model® (CM) for pharmaceutical evaluations and the 
Academy of Managed Care Pharmacy (AMCP) Format (Format) for formulary submis-
sions were developed to streamline health technology assessment (HTA). The CM is 
specific to European HTAs, while the Format is specific to US managed care. This study 
aims to compare these approaches to identify areas of overlap, and differing elements 
that may reflect regional values and preferences. MethOds: The CM for pharmaceu-
ticals (Version 2.1) and the Format (Version 3.1) were examined and analyzed by two 
reviewers. A table of 17 characteristics was created to evaluate which elements align 
or do not align. Results: Of the 17 characteristics, 5 were found to be aligned, 5 were 
somewhat aligned, and 7 were not at all aligned. The CM provides more detailed guid-
ance (388 pages of guidance, 447 pages total) on desired data sources and rationale, 
whereas the Format provides only a short overview of requirements and methodol-
ogy (17 pages of guidance, 95 total). There is general alignment in terms of requiring 
information on burden of disease, existing treatment options, clinical effectiveness, 
and economic analyses, however within these overarching themes, certain variations 
exist. For example, the CM suggests cost-effectiveness, -utility or -benefit analyses, 
while the Format suggests only cost-effectiveness analyses. In addition, the CM con-
tains additional sections, including ethical analysis, organizational aspects, social 
aspects, and legal aspects. Alternatively, the Format contains an addendum specific to 
use of comparative effectiveness research (CER), as defined in the US, stipulating that 
CER studies reflect patient preferences. It also contains a separate addendum specific 
to specialty pharmaceuticals. cOnclusiOns: While the CM and Format require simi-
lar information to be submitted, certain regional values and health system differences 
are reflected in the varying approaches. Trans-Atlantic collaboration could be helpful 
in standardizing characteristics across these frameworks.
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Objectives: Biologics have made substantial contribution in a number of dis-
eases, but the high cost of therapy in the arena of cost containment impacting 
their accessibility and sustainability. Biosimilars are a viable alternative after patent 
expiry of many first generation originator biologics. Expecting a 20-30% difference 
in price from a branded product, budget impact is being considered an impor-
tant area driving the market access of these products. Hence, we reviewed the 
published budget impact analysis (BIA) of the biosimilars conducted in different 
countries’. MethOds: We searched the PubMed, ISPOR, google scholar database 
etc. for English language articles with search terms “budget impact” OR “budget 
analysis” AND “biosimilar” OR “subsequent entry biological” OR “follow-on biologi-
cal”. The methodology of analysis and the major outcomes such as cost saving and 
additional patients treated were reviewed from the included studies. Results: 
Articles reporting the BIA of biosimilars were identified. The studies with BIA were 
segregated based on the countries. The source of funding, model used, and descrip-
tion provided around the model for the BIA was identified. The budget savings 
projected over 2015-2019 ranged from 95.8mn to 433mn at 10% and 30% discount, 
respectively, for UK, Italy, France, and Germany. The net benefit of 29.8mn over 3 
years period resulted in treatment of 1025 to 1615 more patients yearly. ISPOR BIA 
good practice II task force guidance was used to assess the analytical framework, 
data sources, and reporting format. cOnclusiOns: The use of biosimilars seems 
to economically attractive, probably due to cost-savings and additional patients’ 
treatment. However, there is low availability of BIAs for biosimilars, where they 
were introduced long back and/or no availability in countries where just entered the 
market. This potential raises the need for highly robust BIAs, thus, aid in decision-
making for judicious allocation of the budget.
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Objectives: Healthcare contributes a major proportion of public expenditures. 
The Finnish publicly funded healthcare system consists of primary and secondary 
healthcare services. Currently, specialized healthcare is responsible of 45-55% of 
total healthcare expenditures. The aim was to clarify the current and projected 
future costs for both primary and secondary healthcare. MethOds: This register-
based study was performed in a selected area covering approximately 200,000 
inhabitants. The data set consists of 1,55 million healthcare contacts to primary 
or secondary healthcare during 2013. All events were matched to individuals with 
the unique national identification code, in order to obtain the per-patient costs in 
different ages. In the future cost projections, it was assumed the per-patient-costs 
